Advertisement

Der Anaesthesist

, Volume 57, Issue 4, pp 382–390 | Cite as

Medikamente zur postoperativen Schmerztherapie: Bewährtes und Neues

Teil 1: Nichtopioide
  • J. Jage
  • R. Laufenberg-Feldmann
  • F. Heid
Klinische Pharmakologie

Zusammenfassung

Im ersten Teil des Übersichtsartikels werden perioperative Aspekte der Anwendung von Nichtopioiden (Paracetamol, Metamizol, traditionelle nichtsteroidale antiphlogistische Rheumatika, Coxibe) diskutiert; im zweiten Teil folgen die Opioide (schwach: Tramadol, Tilidin mit Naloxon; stark: Piritramid, Morphin, Oxycodon, Hydromorphon, Fentanyl, Methadon, Buprenorphin) und einige Koanalgetika (Gabapentinoide, Ketamin). Zentraler Punkt der Übersicht ist die Darstellung von Nutzen und Risiken der Substanzen (Analgesie vs. Nebenwirkungen), um dem Anwender die Differenzialindikation bei Patienten mit renalen, gastrointestinalen, kardiozirkulatorischen oder hepatischen Vorerkrankungen zu erleichtern. Neue Aspekte der Anwendung von Gabapentinoiden und Ketamin werden ebenfalls diskutiert.

Schlüsselwörter

Postoperative Schmerztherapie Paracetamol Metamizol Traditionelle NSAR Coxibe Opioide Gabapentinoide Ketamin 

Drugs for postoperative analgesia: routine and new aspects

Part 1: Non-opioids

Abstract

In part 1 of this review the perioperative aspects of the use of non-opioids (acetaminophen, dipyrone, traditional NSAR, coxibs) and in part 2 of opioids (weak opioids: tramadol, tilidine with naloxone, strong opioids: morphine, piritramide, oxycodone, hydromorphone, fentanyl, methadone, buprenorphine) and coanalgesics (gabapentinoids, ketamine) will be discussed. The main aim is to describe the relationship between analgesic efficacy and side effects to make clinical decisions easier in patients with preoperative renal, gastrointestinal, cardiovascular and other diseases. Some new aspects concerning perioperative administration of gabapentinoids and ketamine in patients with perioperative neuropathic pain are discussed.

Keywords

Postoperative analgesia Acetaminophen Dipyrone Coxibs Traditional NSAR Opioids Gabapentinoids Ketamine 

Notes

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: Der korrespondierende Autor hat Vorträge auf Honorarbasis für die Firmen Avenits, Bristol Myers-Squibb, Grünenthal, Janssen-Cilag, MSD, Mundipharma gehalten.

Literatur

  1. 1.
    Antman EM, Bennett JS, Daugherty et al. (2007) Use of nonsteroidal anti-inflammatory drugs. An update for clinicians. A scientific statement from the American Heart Association. Circulation 115: 1634–1642PubMedCrossRefGoogle Scholar
  2. 2.
    Böger RH, Schmidt G (2007) Analgetika. In: Schwabe U, Paffrath D (Hrsg) Arzneiverordnungsreport 2006. Springer, Berlin Heidelberg New York Tokio, S 273–290Google Scholar
  3. 3.
    Burger W, Chemnitius J-M, Kneissl GD, Rücker G (2005) Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. J Intern Med 257: 399–414PubMedCrossRefGoogle Scholar
  4. 4.
    Catella-Lawson F, Reilly MP, Kapoor SC et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809–1817PubMedCrossRefGoogle Scholar
  5. 5.
    Dersh J, Polatin PB, Gatcehl RJ (2002) Chronic pain and psychopathology: research findings and theoretical considerations. Psychosom Med 64: 773–786PubMedCrossRefGoogle Scholar
  6. 6.
    Edwards JE, McQuay HJ (2002) Dipyrone and agranulocytosis: what is the risk? Lancet 360: 1438PubMedCrossRefGoogle Scholar
  7. 7.
    FitzGerald GA (2003) COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2: 879–890PubMedCrossRefGoogle Scholar
  8. 8.
    Forrest JB, Camu F, Greer IA et al. (2002) Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery. Br J Anaesth 88: 227–233PubMedCrossRefGoogle Scholar
  9. 9.
    Furberg C, Psaty B, FitzGerald GA (2005) Parecoxib, valdecoxib, and cardiovascular risk (editorial). Circulation 111: 249PubMedCrossRefGoogle Scholar
  10. 10.
    Garcia Rodriguez LA, González-Pérez A (2005) Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 3: 17–22CrossRefGoogle Scholar
  11. 11.
    Geisslinger G, Peskar BA, Pallapies G et al. (1998) The effects on platelet aggregation and prostanoid biosynthesis of two potent analgesics: ketorolac, tromethamine and dipyrone. Thromb Haemost 76: 592–597Google Scholar
  12. 12.
    Gislason GH, Jacobsen S, Rasmussen JN et al. (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Circulation 113: 2906–2913PubMedCrossRefGoogle Scholar
  13. 13.
    Gogarten W, van Aken H, Büttner J et al. (2007) Rückenmarksnahe Regionalanästhesien und Thromboembolieprophylaxe/antithrombotische Medikation. Anaesthesiol Intensivmed 48: 109–124Google Scholar
  14. 14.
    Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 4–15PubMedCrossRefGoogle Scholar
  15. 15.
    Hedenmalm K, Spigset O (2002) Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol 58: 265–274PubMedCrossRefGoogle Scholar
  16. 16.
    Hinz B, Brune K (1999) Spezifische COX-2-Inhibitoren: Perspektiven einer Therapie mit neuen analgetischen und antiinflammatorischen Wirkstoffen. Wien Klin Wochenschr 111:103–112PubMedGoogle Scholar
  17. 17.
    Hyllested M, Jones S, Pedersen JL, Kehlet H (2002) Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review. Br J Anaesth 88: 199–214PubMedCrossRefGoogle Scholar
  18. 18.
    Kehlet H, Jensen T, Woolf C (2006) Persistent postsurgical pain: risk factors and prevention. Lancet 367: 1618–1625PubMedCrossRefGoogle Scholar
  19. 19.
    Kehlet HM, Werner MU (2003) Role of paracetamol in the acute pain management. Drugs 63 [Spec 2]: 15–22Google Scholar
  20. 20.
    MacDonald TM, Wei L (2003) Effect of ibuprofen on cardiovascular effect of aspirin. Lancet 361: 573–574PubMedCrossRefGoogle Scholar
  21. 21.
    Marret E, Kurdi O, Zufferey P, Bonnet F (2005) Effects of nonsteroidal antiinflammatory drugs on patient controlled analgesia morphine side effects. Anesthesiology 102: 1249–1260PubMedCrossRefGoogle Scholar
  22. 22.
    McQuay HJ, Moore A (2006) NSAIDs and Coxibs: clinical use. In: McMahon SB, Koltzenburg (eds) Wall and Melzack’s textbook of pain, 5th edn. Elsevier Churchill Livingston, Philadelphia, pp 471–480Google Scholar
  23. 23.
    Moiniche S, Kehlet H, Dahl JB (2002) A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief. Anesthesiology 96: 725–741PubMedCrossRefGoogle Scholar
  24. 24.
    Nussmeier NA, Whelton AA, Brown MT et al. (2005) Complications of the COX-2-inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081–1091PubMedCrossRefGoogle Scholar
  25. 25.
    Nussmeier NA, Whelton AA, Brown MT et al. (2006) Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology 104: 518–526PubMedCrossRefGoogle Scholar
  26. 26.
    Ott E, Nussmeier NA, Duke PC et al. (2003) Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125: 1481–1492PubMedCrossRefGoogle Scholar
  27. 27.
    Patrignani P, Panara MR, Sciulli MG, et al. (1997) Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 48: 623–631PubMedGoogle Scholar
  28. 28.
    Planet G (2007) Comparison of creatinine clearance estimates with routine measured clearance. Clin Biochem 40: 124–147PubMedCrossRefGoogle Scholar
  29. 29.
    Steffen P, Krinn E, Möller A et al. (2002) Metamizol and diclofenac profoundly reduce opioid consumption after minor trauma surgery. Acute Pain 4: 71–75CrossRefGoogle Scholar
  30. 30.
    Thummel KE, Shen DD, Isoherranen N, Smith HE (2006) Design and optimization of dosage regimens: pharmacokinetic data. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman and Gilman’s The pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York Chicago San Francisco, pp 1787–1888Google Scholar
  31. 31.
    Wasan AD, Davar G, Jamison R (2005) The association between negative affect and opioid analgesia in patients with discogenic low back pain. Pain 117: 450–461PubMedCrossRefGoogle Scholar
  32. 32.
    Yaksh TL, Dirig DM, Conway CM et al. (2001) The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 21: 5847–5853PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2008

Authors and Affiliations

  1. 1.Klinik für AnästhesiologieJohannes Gutenberg-UniversitätMainzDeutschland

Personalised recommendations